Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.
Prostate Cancer
DRUG: QLG1080
Sustained castration rate of serum testosterone, The cumulative probability of serum testosterone levels reaching and maintaining castration levels (â‰¤50 ng/dL or 1.7 nmol/L), From study day 29 to the end of the study
The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.